LICENSE AND COLLABORATION AGREEMENT by and between PFIZER INC. and [***] DATED AS OF NOVEMBER 21, 2022License and Collaboration Agreement • February 13th, 2023 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is dated as of the 21st day of November, 2022 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at [***] (“Pfizer”), [***] a corporation organized and existing under the laws of Delaware with offices at [***] (“Licensee”), and solely with respect to Section 11.4, Roivant Sciences Ltd., a corporation organized and existing under the laws of Bermuda with offices at [***] (“Roivant”). Licensee and Pfizer (and, solely with respect to Section 11.4, Roivant) may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • February 13th, 2023 • Roivant Sciences Ltd. • Pharmaceutical preparations • Delaware
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of November 21, 2022, by and among [***] a Delaware corporation with offices at [***] (the “Company”), Roivant Sciences Ltd., an exempted limited company incorporated under the laws of Bermuda with its registered office at [***] (“Roivant”), Pfizer Inc., a Delaware corporation with offices at [***] (“Pfizer”) and each other Person that becomes an “Investor” hereunder after the date hereof in accordance with this Agreement. Each of the Company and the Investors shall be referred to herein as a “Party” and collectively as the “Parties”.
